Form 4: Arcadia Biosciences CFO Kawakami Increases Stake in Company via Employee Stock Purchase Plan

Mark Kawakami, CFO of Arcadia Biosciences, acquired 700 shares of common stock at $2.49 per share through the company's Employee Stock Purchase Plan (ESPP).

Summary

• On February 3, 2025, Mark Kawakami, the Chief Financial Officer of Arcadia Biosciences, Inc., purchased 700 shares of the company's common stock.
• The purchase was made through the company's 2015 Employee Stock Purchase Plan (ESPP) at a price of $2.49 per share.
• Following the transaction, Kawakami directly owns 2,681 shares of Arcadia Biosciences.
• The ESPP allows employees to purchase shares at 85% of the closing price of the company's common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CFO's purchase indicates confidence, but it's a routine transaction.

Positives

• The CFO's participation in the ESPP demonstrates confidence in the company's future.
• The ESPP provides employees with an opportunity to invest in the company's success.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to participate in employee stock purchase plans.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Arcadia Biosciences, RKDA, Mark Kawakami, CFO, Employee Stock Purchase Plan, ESPP, Form 4, Beneficial Ownership, Common Stock